Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) ...

Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. | Sanofi’s $1.7 billion rare disease bet ...

Thermo Fisher Scientific’s plan for growth is paying off as the biopharma service provider and supplier posted a sales bump ...

Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the ...

Following three years of internal development, Expedition Medicines is taking flight. The company is supported by a $50 ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...

In one of the biggest healthcare acquisitions of its kind this year, medtech diagnostics specialist Hologic will go private ...

Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and ...

Parikh is backed up by experienced CRO leader William Gannon Jr., M.D., who is LyfeSci’s chief medical officer. Gannon has ...

Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...